Consensus $152.1M. The company said, “As a result of slower than expected sales in the first half, significantly compounded by the ongoing reimbursement issue, AVITA has adjusted its full-year guidance as follows: Full-year 2025 revenue guidance to a range of $76 million to $81 million compared to previous guidance of $100 million to $106 million. This new guidance reflects growth of approximately 19% to 27% over full-year 2024 revenue. Cash flow break-even in the second quarter of 2026 and GAAP profitability in the third quarter of 2026, instead of the previously anticipated second half of 2025 and fourth quarter of 2025, respectively.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
- Avita Medical chair Lou Panaccio steps down, Cary Vance succeeds
- Avita Medical Appoints Dr. Michael Tarnoff to Board
- RCEL Earnings this Week: How Will it Perform?
- Avita Medical’s Cohealyx Study: A Promising Step in Wound Care Innovation
- Avita Medical’s Cohealyx Study: A Game Changer in Wound Management?